Effects of Dipeptidyl Peptidase-4 Inhibitors on Renal Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Bae, Jae Hyun | - |
dc.contributor.author | Kim, Sunhee | - |
dc.contributor.author | Park, Eun-Gee | - |
dc.contributor.author | Kim, Sin Gon | - |
dc.contributor.author | Hahn, Seokyung | - |
dc.contributor.author | Kim, Nam Hoon | - |
dc.date.accessioned | 2021-09-01T18:06:58Z | - |
dc.date.available | 2021-09-01T18:06:58Z | - |
dc.date.created | 2021-06-19 | - |
dc.date.issued | 2019-03 | - |
dc.identifier.issn | 2093-596X | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/67133 | - |
dc.description.abstract | Background: To investigate the effects of dipeptidyl peptidase-4 (DPP-4) inhibitors on renal outcomes in patients with type 2 diabetes. Methods: MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials were searched to identify randomized controlled trials (RCTs) of DPP-4 inhibitors from inception to September 2017. We selected eligible RCTs comparing DPP-4 inhibitors with placebo or other antidiabetic agents and reporting at least one renal outcome. A meta-analysis was conducted to calculate standardized mean differences, weighted mean differences (WMDs), relative risks (RRs), and 95% confidence intervals (CIs) for each renal outcome. Results: We included 23 RCTs with 19 publications involving 41,359 patients. Overall changes in urine albumin-to-creatinine ratio were comparable between DPP-4 inhibitors and controls (P=0.150). However, DPP-4 inhibitors were associated with significantly lower risk of incident microalbuminuria (RR, 0.89; 95% CI, 0.80 to 0.98; P=0.022) and macroalbuminuria (RR, 0.77; 95% CI, 0.61 to 0.97; P=0.027), as well as higher rates of regression of albuminuria (RR, 1.22; 95% CI, 1.10 to 1.35; P< 0.001) compared with controls. Although DPP-4 inhibitors were associated with small but significantly lower estimated glomerular filtration rate (WMD, -1.11 mL/min/1.73 m(2); 95% CI, -1.78 to -0.44; P=0.001), there was no difference in the risk of end-stage renal disease between two groups (RR, 0.93; 95% CI, 0.76 to 1.14; P=0.475). Conclusion: DPP-4 inhibitors had beneficial renal effects mainly by reducing the risk of development or progression of albuminuria compared with placebo or other antidiabetic agents. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | KOREAN ENDOCRINE SOC | - |
dc.subject | DOUBLE-BLIND | - |
dc.subject | DPP-4 INHIBITION | - |
dc.subject | CARDIOVASCULAR OUTCOMES | - |
dc.subject | INITIAL COMBINATION | - |
dc.subject | GLYCEMIC CONTROL | - |
dc.subject | GLP-1 RECEPTOR | - |
dc.subject | LINAGLIPTIN | - |
dc.subject | SITAGLIPTIN | - |
dc.subject | METFORMIN | - |
dc.subject | PLACEBO | - |
dc.title | Effects of Dipeptidyl Peptidase-4 Inhibitors on Renal Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, Sin Gon | - |
dc.contributor.affiliatedAuthor | Kim, Nam Hoon | - |
dc.identifier.doi | 10.3803/EnM.2019.34.1.80 | - |
dc.identifier.scopusid | 2-s2.0-85065021349 | - |
dc.identifier.wosid | 000462184200010 | - |
dc.identifier.bibliographicCitation | ENDOCRINOLOGY AND METABOLISM, v.34, no.1, pp.80 - 92 | - |
dc.relation.isPartOf | ENDOCRINOLOGY AND METABOLISM | - |
dc.citation.title | ENDOCRINOLOGY AND METABOLISM | - |
dc.citation.volume | 34 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 80 | - |
dc.citation.endPage | 92 | - |
dc.type.rims | ART | - |
dc.type.docType | Review | - |
dc.identifier.kciid | ART002452695 | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | Endocrinology & Metabolism | - |
dc.relation.journalWebOfScienceCategory | Endocrinology & Metabolism | - |
dc.subject.keywordPlus | DOUBLE-BLIND | - |
dc.subject.keywordPlus | DPP-4 INHIBITION | - |
dc.subject.keywordPlus | CARDIOVASCULAR OUTCOMES | - |
dc.subject.keywordPlus | INITIAL COMBINATION | - |
dc.subject.keywordPlus | GLYCEMIC CONTROL | - |
dc.subject.keywordPlus | GLP-1 RECEPTOR | - |
dc.subject.keywordPlus | LINAGLIPTIN | - |
dc.subject.keywordPlus | SITAGLIPTIN | - |
dc.subject.keywordPlus | METFORMIN | - |
dc.subject.keywordPlus | PLACEBO | - |
dc.subject.keywordAuthor | Albuminuria | - |
dc.subject.keywordAuthor | Diabetes complications | - |
dc.subject.keywordAuthor | Diabetes mellitus, type 2 | - |
dc.subject.keywordAuthor | Diabetic nephropathies | - |
dc.subject.keywordAuthor | Dipeptidyl-peptidase IV inhibitors | - |
dc.subject.keywordAuthor | Glomerular filtration rate | - |
dc.subject.keywordAuthor | Kidney failure, chronic | - |
dc.subject.keywordAuthor | Meta-analysis | - |
dc.subject.keywordAuthor | Systematic review | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.